| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-281 | |
| Phytochemical name or plant extracts | Resiniferatoxin | |
| PMID | 31881661 | |
| Literature evidence | However, the side effects of these treatments have led to a rise in searching for alternative therapies. | |
| IUPAC name | [(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate | |
| Phytochemicals’ class or type of plant extracts | Diterpenoid | |
| Source of phytochemicals or plant Extracts | Euphorbia bicolor | |
| Geographical availability | Arkansas, Louisiana, Oklahoma, Texas | |
| Plant parts | Latex | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | The latex extract, resiniferatoxin (RTX) and rutin induced antiproliferative activities in all cell lines in a dose-dependent manner, but not in human normal primary dermal fibroblast cultures. | |
| Cell line/ mice model | MDA-MB-231, MDA-MB-469 | |
| Additional information | Treatments with latex extract in combination with RTX or rutin reduced even more the proliferation of MCF-7 breast carcinoma compared to the individual latex, RTX, and rutin treatments. E. bicolor latex phytochemicals could contribute to developing commercial therapeutic agents for breast cancer treatment. | |
| PubChem ID | 5702546 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:345779-1 | |
| Safety | NA |